Skip to contentL
Lineage Cell Therapeutics, Inc.
L
LCTXLineage Cell Therapeutics, Inc. Q2 2021 · 10-Q
Revenue$512.00K$512.00K+32.6% vs Q2 2020 Net Income-$4.79M-$4.79MN/M vs Q2 2020 EPS Diluted-$0.03-$0.03N/M vs Q2 2020 Gross Profit$387,000+24.4% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lineage Cell Therapeutics, Inc. · CIK 876343 · Engraved from SEC EDGAR
Operating Cash Flowderived-$5,416,000N/M Free Cash Flowderived-$5,545,000N/M Margins · derivedGross margin75.6%−5.0 pt vs Q2 2020
Operating margin-1382.8%+275.7 pt vs Q2 2020
Net margin-935.2%+754.5 pt vs Q2 2020
ended Jun 30, 2021 · filed Aug 12, 2021 · 43 d after period end